Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02879006
Other study ID # GCO 16-1384
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date August 2016
Est. completion date November 2020

Study information

Verified date August 2020
Source Icahn School of Medicine at Mount Sinai
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is testing the use E-B-FAHF-2 Chinese herbal therapy in combination with multi-food oral immunotherapy (OIT) and Xolair® (Omalizumab) to help children and adults who are allergic to foods be able to safely tolerate food allergens. Specifically in this protocol, the food allergens are milk, egg, peanut, almond, cashew, hazelnut, walnut, sesame, and/or wheat. Omalizumab is considered an investigational drug for the treatment of food allergies in children and adults. Investigational means it has not been approved by the Food and Drug Administration (FDA) for use in the U.S. The researchers hope to learn whether the addition of Chinese herbal therapy (E-B-FAHF-2) can improve the outcome of sustained unresponsiveness (which is the ability to consume a food allergen and pass an oral food challenge after being off treatment for 3 months) as compared to placebo (i.e. subjects with OIT/Omalizumab + herbal vs. OIT/Omalizumab + placebo), and will help adults and children be able to safely ingest the foods they are allergic to.


Description:

Prior studies have shown that this Chinese herbal formulation is safe and well-tolerated in food allergic individuals. While oral immunotherapy (OIT) can lead to desensitization, it remains uncertain whether this treatment can lead to lasting protection. Therefore, this study aims to use the Chinese herbal formula in combination with OIT to determine whether sustained protection can be achieved. All subjects will receive multi-allergen OIT, along with a 4 month course of omalizumab to provide added safety for the initial dose escalation and build up phases. Subjects will be randomized to receive active Chinese herbal formula or placebo. Subjects will be treated with OIT for 2 years and then food challenges will be performed to assess for desensitization. For those who achieve desensitization, all treatments will be discontinued and food challenges will be performed 3 months later to assess for sustained unresponsiveness.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 33
Est. completion date November 2020
Est. primary completion date November 2020
Accepts healthy volunteers No
Gender All
Age group 6 Years to 40 Years
Eligibility Inclusion Criteria:

- 6 through 40 years

- At least one of the following for each of the 3 study allergens: serum IgE >4 kU/L or skin prick test >6mm

- dose limiting symptoms at a cumulative dose of <=444 mg protein for 3 allergens as screening double-blind, placebo-controlled food challenge

- use of an effective method of contraception by females of child-bearing potential

- ability to ingest oat or corn with no allergic reaction

Exclusion Criteria:

- If baked milk or egg are tolerated (assessed by clinical report), then milk or egg may not be included as a study allergen

- Any disorder in which epinephrine is contraindicated such as coronary artery disease, uncontrolled hypertension, and serious ventricular arrhythmias

- History of other chronic disease requiring therapy (other than asthma, atopic dermatitis, or rhinitis)

- History of eosinophilic gastrointestinal disease

- Current participation in any other interventional study

- Investigational drug use within 90 days

- Subject is on build-up phase of any allergen immunotherapy (prior to maintenance dosing)

- Current uncontrolled moderate to severe asthma as defined by:

- FEV1 value <80% predicted (or PFR if unable to perform spirometry) or any clinical features of moderate or severe persistent asthma baseline severity (as defined by the 2007 NHLBI Guidelines) and greater than high daily doses of inhaled corticosteroids (as defined for children and adults using dosing tables from the 2007 NHLBI Guidelines).

- Use of steroid medications in the following manners: history of daily oral steroid dosing for >1 month during the past year, having 1 burst or steroid course within the past 6 months, or having >1 burst oral steroid course within the past 12 months.

- Asthma requiring >1 hospitalization in the past year for asthma or >1 ED visit in the past 6 months for asthma.

- Use of systemic steroid medications (IV, IM or oral) for indications other than asthma for > 3 weeks within the past 6 months

- Inability to discontinue antihistamines for the initial day of escalation, skin testing or DBPCFC

- Use of Xolair® (omalizumab) within the past 6 months

- Known sensitivity to Xolair® (omalizumab) or to the class of study drugs

- Body weight more than 90 kg, or subjects with weight-IgE combination that yields a dose requirement greater than 600 mg dosing

- Use of beta-blockers (oral), (ACE) inhibitors, angiotensin-receptor blockers or calcium channel blockers

- Pregnancy or lactation

- Inability to swallow placebo capsules

- Mental illness or history of drug or alcohol abuse that, in the opinion of the investigator, would interfere with the subject's ability to comply with study requirements

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Chinese Herbal Medication
Capsules, 26 month course, starting 2 months pre-OIT
Placebo
Placebo capsules that look identical to E-B-FAHF-2, 26 month course, starting 2 months pre-OIT
Omalizumab
4 months course, starting 2 months pre-OIT through the 2 month build-up phase
Multi OIT
24 months of multi OIT (maintenance dose of 1gm each food allergen)

Locations

Country Name City State
United States Johns Hopkins University Baltimore Maryland
United States Icahn School of Medicine at Mount Sinai New York New York

Sponsors (1)

Lead Sponsor Collaborator
Xiu-Min Li

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sustained unresponsiveness Sustained unresponsiveness evaluated by the absence of dose-limiting symptoms to a cumulative dose of 4,444 protein. month 29
Secondary Desensitizing to 4444mg Number of participants tolerating a cumulative dose of 4,444mg of food allergen protein. month 26
Secondary High level of desensitization to 7444mg or higher Number of participants tolerating a cumulative dose of 7,444mg or higher (max of 10,444mg) of food allergen protein month 26
See also
  Status Clinical Trial Phase
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT05839405 - Food Allergy in the Brain
Completed NCT02552537 - iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions Phase 4
Completed NCT01634737 - Crustacean Allergy and Dust Mites Sensitization N/A
Recruiting NCT05521711 - TRADE Trial - Tree Nut Immunotherapy Route Development and Evaluation N/A
Completed NCT05072665 - Fast Allergy Sensitivity Test N/A
Active, not recruiting NCT04887441 - Allergology: Information, Data and Knowledge Organization
Recruiting NCT03265262 - The Basophil Activation Test as a Diagnostic Tool in Pediatric Food Allergy N/A
Completed NCT04186949 - Early Origins of Allergy and Asthma
Completed NCT02490007 - Pertussis Immunisation and Food Allergy
Recruiting NCT03151252 - Improvement of Foodallergy Diagnostic in Gastrointestinal Tract N/A
Completed NCT02159833 - Intranasal Diagnostics in Food Allergy: a Feasibility Study N/A
Completed NCT02354729 - Encouraging Allergic Young Adults to Carry Epinephrine N/A
Completed NCT02377284 - Prevention and Management of Food Allergies N/A
Completed NCT02640560 - One-year Survey of Anaphylaxis in Outpatient Children Allergic to Peanuts, Walnuts/Hazelnuts, Shellfish N/A
Enrolling by invitation NCT06097572 - Improved Diagnostics in Food Allergy Study N/A
Recruiting NCT04606615 - Skin Barrier Abnormalities and Oxidative Stress Response
Recruiting NCT05785299 - Clinical Versus Home Introduction of Milk in Children With Non-IgE-mediated Cow's Milk Allergy N/A
Not yet recruiting NCT06112873 - Quality of Life in Food Allergy: Validation of Three Mini-questionnaires
Completed NCT03337802 - Effect of Mediterranean Diet During Pregnancy on the Onset of Overweight and Obesity in the Offspring N/A